SCHEMBL3388292

SCHEMBL3388292

Nc1ccc(-c2cnco2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.47
IMPDH2 P12268 1/20 0.45
IMPDH1 P20839 1/20 0.45
ROCK2 O75116 2/20 0.43
PTK2 Q05397 1/20 0.42
NOTUM Q6P988 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 1/20 0.40
PKM P14618 1/20 0.40
CYP4F2 P78329 2/20 0.39
CYP4A11 Q02928 2/20 0.39
KEAP1 Q14145 1/20 0.37
ADRA2A P08913 2/20 0.36
ADRA2B P18089 2/20 0.36
ADRA2C P18825 2/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30753615 1.00 MAP4K4 (0.47) MAP4K4IMPDH2IMPDH1ROCK2PTK2
SCHEMBL29621110 0.77 GAA (0.58) MAP4K4ROCK2PTK2NOTUMGAA
SCHEMBL22925607 0.77 ROCK2 (0.43) MAP4K4ROCK2PTK2NOTUMGAA
SCHEMBL17193258 0.77 NOTUM (0.58) MAP4K4ROCK2PTK2NOTUMGAA
SCHEMBL6612464 0.77 GAA (0.58) MAP4K4ROCK2PTK2NOTUMGAA
SCHEMBL9284896 0.77 LMNA (0.58) MAP4K4IMPDH2IMPDH1ROCK2PTK2
SCHEMBL29620980 0.77 NOTUM (0.58) MAP4K4ROCK2PTK2NOTUMGAA
SCHEMBL22925543 0.75 ROCK2 (0.40) MAP4K4ROCK2PTK2NOTUMGAA
SCHEMBL1160951 0.74 PKM (0.64) MAP4K4IMPDH2IMPDH1PTK2NOTUM
SCHEMBL20476221 0.74 MAP4K4 (0.47) MAP4K4IMPDH2IMPDH1ROCK2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606544-B2 JAK1 selective kinase inhibitor DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2026-04-21 US disclosed
EP-3956322-B1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-05-14 EP disclosed
EP-3583105-B1 PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES GILEAD SCIENCES INC (US) 2024-02-07 EP disclosed
CN-113710664-B JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2024-01-26 CN disclosed
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-07-14 US disclosed
CN-113710664-A JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2021-11-26 CN disclosed
WO-2020211839-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-10-22 WO disclosed
US-10336762-B2 Pyrrolo[1,2-b]pyridazine derivatives GILEAD SCIENCES, INC. (US) 2019-07-02 US disclosed
US-10336762-B2 Pyrrolo[1,2-b]pyridazine derivatives GILEAD SCIENCES, INC. (US) 2019-07-02 US disclosed
WO-2018152368-A1 PYRROLO [1,2-B] PYRIDAZINE DERIVATIVES GILEAD SCIENCES, INC. (US) 2018-08-23 WO disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 WO disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR JAK1, JAK2, JAK3 MAP4K4 96/4885IMPDH2 3826/4885IMPDH1 2384/4885
US-20100056524-A1 Compound NR3C2, NR3C1, NR2E3 MAP4K4 738/4885IMPDH2 4458/4885IMPDH1 4350/4885
US-10336762-B2 Pyrrolo[1,2-b]pyridazine derivatives SDHB, CYP4F2, CYP1B1 MAP4K4 1737/4885IMPDH2 187/4885IMPDH1 191/4885
US-12606544-B2 JAK1 selective kinase inhibitor JAK1, JAK2, JAK3 MAP4K4 470/4885IMPDH2 4630/4885IMPDH1 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.